(R)-Crizotinib-d5 (piperidine-3,3,4,5,5-d5)

(R)-Crizotinib-d5 (piperidine-3,3,4,5,5-d5) is a deuterated form of the popular medication Crizotinib. It is a potent inhibitor of the receptor tyrosine kinase ALK (anaplastic lymphoma kinase), and has been approved by the FDA for the treatment of ALK-positive non-small cell lung cancer (NSCLC). The deuterium substitution in (R)-Crizotinib-d5 (piperidine-3,3,4,5,5-d5) improves its pharmacokinetic properties, which enables it to have a longer half-life in the body, and it also reduces the number of metabolic breakdown products, which helps to reduce the toxicity of the medication. (R)-Crizotinib-d5 (piperidine-3,3,4,5,5-d5) is usually administered orally, and it works by inhibiting the activity of the ALK protein, which is overexpressed in certain types of cancer cells. By inhibiting ALK, (R)-Crizotinib-d5 (piperidine-3,3,4,5,5-d5) prevents the growth and proliferation of cancer cells, and also induces cell death. The medication has been found to be effective in treating ALK-positive NSCLC, and has also shown promise in treating other types of cancer, such as neuroblastoma and inflammatory myofibroblastic tumor. The chemical formula of (R)-Crizotinib-d5 (piperidine-3,3,4,5,5-d5) is C21H22D5ClN6O, and its molecular weight is 422.98 g/mol. The medication is stable under normal conditions, and is soluble in water, ethanol, and dimethyl sulfoxide. (R)-Crizotinib-d5 (piperidine-3,3,4,5,5-d5) has a purity of >99% and is available from a number of chemical suppliers.